Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?
Hims & Hers Health, Inc. (HIMS - Free Report) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 50.5% loss over the past four weeks.
The recent surge in Hims & Hers Health Inc.'s shares can be attributed to the strong fourth-quarter and full-year 2024 results, highlighted by a 95% YoY increase in quarterly revenue to $246.6 million and 65% full-year revenue growth to $872 million, alongside positive adjusted EBITDA margins. Investor confidence is further boosted by the company’s 2025 outlook, projecting revenue between $1.17 billion and $1.20 billion, and continued profitability. Despite regulatory challenges around compounded weight-loss medications, Hims & Hers’ strategic diversification and 48% YoY subscriber growth to 1.5 million underpin optimism for sustained growth.
This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +120%. Revenues are expected to be $535.94 million, up 92.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Hims & Hers Health, the consensus EPS estimate for the quarter has been revised 18% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on HIMS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Hims & Hers Health belongs to the Zacks Medical Info Systems industry. Another stock from the same industry, Fulgent Genetics, Inc. (FLGT - Free Report) , closed the last trading session 1.2% higher at $17.09. Over the past month, FLGT has returned 1.6%.
For Fulgent Genetics, the consensus EPS estimate for the upcoming report has changed -26.9% over the past month to -$0.19. This represents a change of -1800% from what the company reported a year ago. Fulgent Genetics currently has a Zacks Rank of #4 (Sell).